Our company is focusing on R&D of small-molecule drugs for advancing best-in-class therapies to improve human lives. We are based in the San Francisco Bay Area, Chongqing and Shanghai. We have a proven track record of accelerating the discovery of best-in-class potential small-molecule therapeutics to clinical development for cancer and metabolic diseases.
We are supported by excellent management and R&D teams with extensive drug discovery and development expertise. We are now leveraging R&D and commercial expertise from US and China to expand our pipeline globally. We seamlessly integrate the art of traditional medicinal chemistry with the modern technology of structure-based drug design.
We are supported by excellent management and R&D teams with extensive drug discovery and development expertise. We are now leveraging R&D and commercial expertise from US and China to expand our pipeline globally. We seamlessly integrate the art of traditional medicinal chemistry with the modern technology of structure-based drug design.
Services
At Fochon, our mission is to improve people's lives by discovering breakthrough medicines that advance the care of patients who are suffering from life-threatening diseases. Our competitive pipeline represents our mission to tackle the problem of difficult-to-treat diseases head on by creating treatments that focus on rising or validated pharmacological targets and conveying them in ways that tailor to particular disease sub-groups.
Innovation - We tirelessly create revolutionary medicines by developing safe and highly-effective targeted small-molecule drugs with completely independent intellectual property rights. Integrity - We are open, honest, trustworthy and fair in conducting our R&D for company's sustained and steady growth.
At Fochon, we seamlessly integrate the art of traditional medicinal chemistry with the modern technology of structure-based drug design. This integration culminates in our proprietary compound generation, optimization and preclinical/clinical development. Focusing primarily on clinically validated targets & druggable chemical scaffolds with known pharmacophores.
Small molecule discovery and development programmes in the areas of cancer and metabolic diseases. Our pipeline consists of novel, proprietary and highly-selective targeted therapeutics that are in development to potentially treat a broad array of difficult-to treat indications, including cancer and metabolic diseases.
SAF-189 is our proprietary, oral active, highly potent and selective small molecule inhibitor of anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1 (ROS1) for the treatment of ALK-positive or ROS1-positive NSCLC. ALK and ROS1 gene rearrangements are important predictive biomarkers and oncogenic drivers for a subgroup of advanced NSCLC.
Reviews
Be the first to review Fochon Pharma.
Write a Review
